These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11519398)

  • 1. Comprehensive management of patients with type 2 diabetes: establishing priorities of care.
    Kendall DM; Bergenstal RM
    Am J Manag Care; 2001 Aug; 7(10 Suppl):S327-43; quiz S344-8. PubMed ID: 11519398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current treatment approaches to type 2 diabetes mellitus: successes and shortcomings.
    Collins FM
    Am J Manag Care; 2002 Oct; 8(16 Suppl):S460-71. PubMed ID: 12408409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperlipidemia and cardiovascular risk factors in patients with type 2 diabetes.
    Goldberg RB
    Am J Manag Care; 2000 Aug; 6(13 Suppl):S682-91; discussion S692-6. PubMed ID: 11183421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forum One: Current recommendations about intensification of metabolic control in non-insulin-dependent diabetes mellitus.
    Henry RR; Genuth S
    Ann Intern Med; 1996 Jan; 124(1 Pt 2):175-7. PubMed ID: 8554214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dyslipidemia in diabetes mellitus].
    Niemeijer-Kanters SD; Banga JD; Erkelens DW
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):769-74. PubMed ID: 11346913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus.
    Rader DJ
    Am J Med; 2007 Mar; 120(3 Suppl 1):S12-8. PubMed ID: 17320517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type II diabetes mellitus.
    Edelman SV
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
    Florkowski CM
    Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance.
    Kendall DM; Harmel AP
    Am J Manag Care; 2002 Dec; 8(20 Suppl):S635-53; quiz S654-7. PubMed ID: 12510788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients.
    Ji L; Hu D; Pan C; Weng J; Huo Y; Ma C; Mu Y; Hao C; Ji Q; Ran X; Su B; Zhuo H; Fox KA; Weber M; Zhang D; ;
    Am J Med; 2013 Oct; 126(10):925.e11-22. PubMed ID: 23810406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
    Krentz AJ
    Diabetes Obes Metab; 2003 Nov; 5 Suppl 1():S19-27. PubMed ID: 14984018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial.
    Shi X; He J; Lin M; Liu C; Yan B; Song H; Wang C; Xiao F; Huang P; Wang L; Li Z; Huang Y; Zhang M; Chen CS; Obst K; Li W; Yang S; Yao G; Li X
    Am Heart J; 2021 Aug; 238():45-58. PubMed ID: 33957103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological interventions in type 2 diabetes: the role of nurses.
    Rodgers J
    Br J Nurs; 2000 Jul 13-26; 9(13):866-70. PubMed ID: 11261060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H; Goyal RK
    Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.
    Hanefeld M; Traylor L; Gao L; Landgraf W
    Cardiovasc Diabetol; 2017 May; 16(1):66. PubMed ID: 28526014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
    Dailey GE; Mohideen P; Fiedorek FT
    Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.